THIS STORY HAS BEEN FORMATTED FOR EASY PRINTING
Life Sciences: Biotech

FDA warning drives doubts on Epogen drug

By Christopher Rowland
Globe Staff / March 19, 2007

E-mail this article

Invalid E-mail address
Invalid E-mail address

Sending your article

Your article has been sent.

Text size +

A Food and Drug Administration warning about the use of antianemia drugs is increasing pressure on Medicare officials to change payment policies for Amgen Inc.'s Epogen, which accounts for $2 billion in federal kidney-dialysis reimbursements. (Full article: 951 words)

This article is available in our archives:

Globe Subscribers

FREE for subscribers

Subscribers to the Boston Globe get unlimited access to our archives.

Not a subscriber?

Non-Subscribers

Purchase an electronic copy of the full article. Learn More

  • $9.95 1 month archives pass
  • $24.95 3 months archives pass
  • $74.95 1 year archives pass